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but not EGFR and ErbB2, was a significant prognostic fac-
tor in poor survival among patients with gastric cancer.
Conclusions EGFR, ErbB2 and MET genes are frequently 
amplified in gastric carcinoma. EGFR, ErbB2 and MET 
gene amplification is positively correlated with mRNA 
transcription. MET gene amplification correlates with a 
poor prognosis and poor survival in gastric carcinomas.
Keywords EGFR · ErbB2 · MET · Gene amplification · 
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Introduction
Gastric cancer (GC) is the third common cause of can-
cer-related deaths worldwide (Jemal et al. 2011). Despite 
improvement in the therapeutic management, the progno-
sis for patients with advanced or recurrent GC still remains 
poor and with a median survival time of approximately 
1 year (Van Cutsem et al. 2006; Al-Batran et al. 2008; Cun-
ningham et al. 2010). Today, major efforts to discover bio-
markers and new therapeutic options are carried out. These 
biomarkers can help to recognize subgroups of patients in 
order to develop a personalized medicine model for special 
treatments of GC patients.
Copy number alterations (CNAs) in genes are usually 
arise from genomic instability and are common in cancers 
(Stuart and Sellers 2009; Huang and Chuang 2013). The 
increasing gene copy number in the genome of malignant 
tumor cells can result from mainly two genetic mecha-
nisms, polysomy and gene amplification. Polysomy leads 
to a copy number gain, due to extra copies of the entire 
chromosome. The gene amplification refers to the amplifi-
cation of specific gene or a group of genes in a given chro-
mosome (Albertson 2006). CNAs of specific genes may 
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up-regulate signaling pathways involved in enhancing the 
cell proliferation and inhibit the apoptosis in tumor cells. 
Cumulative evidences show an association between CNA 
and prognosis in cancer patients (Beroukhim et al. 2010).
Epidermal growth factor receptors (EGFR) are mem-
bers of the ErbB family, a group of transmembrane recep-
tor tyrosine kinase with key roles in embryonic develop-
ment and cell growth. This family consists of four homolog 
receptors, including EGFR (HER1, ErbB1), HER2 (Neu, 
ErbB2), HER3 (ErbB3) and HER4 (ErbB4) (Yarden and 
Sliwkowski 2001; Casalini et al. 2004). Aberrant EGFR 
signaling pathway plays a central role in the development 
and progression of different human cancers. EGF receptors 
phosphorylate several cellular proteins and regulate mul-
tiple signaling cascades, which lead to cell proliferation, 
angiogenesis, migration, invasion, metastasis and apopto-
sis inhibition (Atmaca et al. 2012). Today, EGFR inhibitors 
for advanced GC are under investigation; however, their 
prognostic role in GC types remains controversial. While 
some first reports have demonstrated an unfavorable out-
come for EGFR overexpression in the cases with resectable 
GC, some studies could not report a significant correlation 
between EGFR overexpression, survival, and favorable 
outcome in patients with resected GC (García et al. 2003; 
Gamboa-Dominguez et al. 2004; Song et al. 2004; Galizia 
et al. 2007; Matsubara et al. 2008; Lieto et al. 2008; Kim 
et al. 2009). Some earlier studies have shown that FGFR 
amplification can increase sensitivity to anti-FGFRs in GC 
both in vitro and in vivo (Takeda et al. 2007; Kim et al. 
2008; Matsumoto et al. 2012; Kato et al. 2013). Their data 
strongly suggest that FGFR amplification might be a prom-
ising target for treatment of GC.
The mesenchymal–epithelial transition (MET) gene is 
a proto-oncogene that encodes the receptor tyrosine kinase 
c-MET. The binding of hepatocyte growth factor protein 
to MET leads to tyrosine phosphorylation of intracellular 
domain of the receptor and activation of downstream pro-
teins of several signaling pathways (Kawakami et al. 2013). 
Oncogenic activation of MET promotes cell proliferation, 
survival, migration, angiogenesis and apoptosis inhibition 
(Birchmeier et al. 2003). Recently, several studies have 
shown the MET gene amplification is one of the causes 
of MET overexpression in GC; however, the frequency of 
MET amplification is various among previous studies (Lee 
et al. 2011, 2012; Huang and Chuang 2013; Kawakami 
et al. 2013).
According to these controversial findings which are 
based on different assay methods and various patient popu-
lations, there is a need for evaluation of EGFR, ErbB2 and 
MET gene amplification in GC patients in different popula-
tions. Therefore, in the current study, we investigated the 
CANs and gene overexpression status of these three genes 
in GC patients. We also analyzed the association of EGFR, 
ErbB2 and MET gene amplification with some clinical and 
pathological features.
Materials and methods
Subjects
Patient samples included 115 formalin-fixed paraffin-
embedded (FFPE) tissues of stomach cancer collected from 
the sporadic GC patients who had surgery from October 
2009 to March 2013. The clinical data of patients were 
obtained from medical records. The overall survival was 
recorded from the time of diagnosis to the time of last fol-
low-up. This study was approved by the Clinical Research 
Ethics Committee in Mazandaran University of Medical 
Science.
DNA and RNA extraction
The tumor samples were cross-checked by a patholo-
gist, and the percentage of tumor cells was at least 90 %. 
Genomic DNA was extracted from microdissected tumor 
tissue samples using the QIAamp DNA FFPE Tissue Kit 
(Qiagen, Hilden, Germany) according to the manufactur-
er’s method. Total RNA was isolated from 50 mg micro-
dissected FFPE using the ReliaPrep FFPE Total RNA 
Miniprep System Kit (Promega, Madison, USA). The 
first-strand cDNA was synthesized using the ProtoScript 
First Strand cDNA Synthesis Kit (New England Biolabs, 
Hitchin, UK) according to the manufacturer’s instruc-
tion. The concentration and quality of DNA and RNA 
were determined using Nanophotometer (Implen, Munich, 
Germany).
Primer design
The qPCR primers were designed for specific recognizing 
genomic DNA of EGFR, ErbB2, MET and Ribonuclease P 
(RNase P) genes, as well as the qRT-PCR primers for spe-
cific recognizing complementary DNA (cDNA) of ErbB1, 
ErbB2, MET and Hypoxanthine–guanine phosphoribosyl-
transferase (HPRT) mRNAs. Primer design was performed 
by Allele ID software (Premier Biosoft, Palo Alto, USA) 
and is analyzed in NCBI and BLAST websites (Table 1).
Gene copy number assay
The quantitative polymerase chain reaction (qPCR) was 
performed to quantify gene copy number in tumor DNA 
samples using primers set and Maxima SYBR Green/ROX 
qPCR Master Mix (Fermentas, Sankt Leon-Rot, Germany) 
in 7500 Real-Time PCR system (Applied Biosystem, 
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Foster City, USA). The reactions for each sample were per-
formed in triplicate. Ribonuclease P (RNase P) was applied 
as the endogenous reference which has two copies in the 
cell. After amplification, the copy number of the target gene 
was calculated from threshold cycle (CT) values by ΔΔCt 
method [ΔΔCt = (Ct of target gene, tumor sample − Ct of 
RNase P, tumor sample) − (average Ct of target gene, con-
trol samples − average Ct of RNase P, control samples)]. 
Because there are two copies of the gene in each cell, the 
copy number is equal to 2× 2−Ct. The cutoff value for 
normal gene copy number was established as mean ± 2 
standard deviation (SD) derived from normal DNA of the 
ten control samples. A value >2 was considered as the 
increasing copy number.
QRT‑PCR assay
The quantitative reverse transcriptase PCR (QRT-PCR) was 
performed to determine mRNA levels of ErbB1, ErbB2 and 
MET using primers set and Maxima SYBR Green/ROX 
qPCR Master Mix. Each sample was tested in triplicate and 
was normalized to HPRT cDNA in 7500 Real-Time PCR sys-
tem. For each gene, the mRNA level was calculated using the 
2
Ct (ΔCt = Ct of target gene − Ct of HPRT gene) method.
Statistical analysis
The associations between gene copy number and clinico-
pathological parameters were analyzed by χ2 test and Fisher’s 
exact test. The correlation of between CNA and mRNA level 
was analyzed by the Spearman correlation test. The survival 
curves were drawn by Kaplan–Meier method, and the differ-
ences between curves were compared by the log-rank test. 
Multivariate analysis was performed by the Cox proportional 
hazards model. Data analyses were performed by SPSS soft-
ware version 19 (SPSS Inc., Chicago, USA). A p value less 
than 0.05 was considered statistically significant.
Results
Gene amplification results
In order to determine the gene amplification of EGFR, 
ErbB2 and MET in tissue samples, we used a Real-Time 
PCR-based copy number assay. Gene amplification was 
defined as values equal or more than three copies. As 
Table 2 shows, EGFR, ErbB2 and MET genes were ampli-
fied in 11.3 % (13/115; range 1.1–27.4 copies), 6.1 % 
(7/115; range 1.6–18.5 copies) and 19.1 % (22/115; range 
2.6–47.8 copies) of cancerous specimens, respectively.
The correlation between gene expression and gene 
amplification in GC samples
In order to compare the mRNA level in groups with ≥3 
copies and <3 copies, we used a QRT-PCR assay on EGFR, 
ErbB2 and MET cDNAs acquired of GC tissue samples. 
Table 1  Used primers in this 
study
S sense, AS antisense, AT annealing temperature
Amplified factors Primers 5′–3′ AT (°C) Genbank accession 
number
Gene copy number
 EGFR S CAAGGCACGAGTAACAAGC 56 NG_007726.3
AS GAGGCTGAGAAAATGATCTTC
 ErbB2 S GAACTGGTGTATGCAGATTGC 56 NG_007503.1
AS AGCAAGAGTCCCCATCCTA
 MET S ATCAACATGGCTCTAGTTGTC 56 NM_000314
AS GGGAGAATATGCAGTGAACC
 RNase P S TTCTGACTTTGCTGCAGATAC 56 NC_018930
AS AGGAATGCAACTTACGTGTC
mRNA expression
 EGFR S GCTTGCATTGATAGAAATGG 55 NM_005228.3
AS GTCGTCTATGCTGTCCTC
 ErbB2 S GCTTTGTGGTCATCCAGAA 55 NM_004448.3
AS CTCCAGCCCTAGTGTCAG
 MET S AGCACTGCTTTAATAGGACAC 55 NM_000245
AS GATCGAGAAACCACAACCTG
 HPRT S TGGACTAATTATGGACAGGAC 55 NM_000194
AS CCTGTTGACTGGTCATTACAA
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Our results have shown, and the mRNA level averages of 
EGFR, ErbB2 and MET (3.21 ± 1.01, 4.31 ± 1.21 and 
3.91 ± 0.71) in ≥3 copies group were significantly higher 
compared with <3 copies group (2.18 ± 0.52, 2.93 ± 0.43 
and 2.33 ± 0.61) (p < 0.001) (Fig. 1). The correlation coef-
ficient test clearly indicated that gene amplification in these 
three genes was positively correlated with mRNA tran-
scription (EGFR: R = 0.631, p = 0.009; ErbB2: R = 0.652, 
p = 0.023; MET: R = 0.715, p < 0.001) (Table 3).
The correlation between gene amplification 
and clinicopathological features in GC patients
All the patients evaluated in this study had undergone 
surgery with histologically confirmed stage. Some of the 
patient features are shown in Table 2. The median follow-
up period was 23 months (range 0–55 months).
In this study, the correlations between EGFR, ErbB2 and 
MET gene amplification and clinicopathological features 
were evaluated. These clinicopathological features included 
sex, age, tumor size, depth of invasion, lymph node metas-
tasis, TNM staging, tumor differentiation and Ki-67 mitotic 
activity index (MI). As Table 2 shows, EGFR and MET gene 
amplification was significantly associated with Ki-67 MI 
(p = 0.022 and p = 0.015). MET amplification was also sig-
nificantly associated with age of ≥60 years (p = 0.021) and 
tumor size of ≥5 cm (p = 0.032). No correlation was seen 
between ErbB2 gene amplification and clinicopathological 
parameters (p > 0.05). The results of the multivariate analy-
sis indicated that MET gene amplification, tumor size and 
Table 2  Relationship between 
gene copy number and 
clinicopathological features in 
patients
Significant p values are in bold
N, number; Tis, carcinoma in situ; T1, lamina propria and submucosa; T2, muscularis propria and subse-
rosa; T3, exposure to serosa; T4, invasion into serosa; TNM, tumor, node, metastases staging system
N Gene copy number
EGFR ErbB2 MET
≥3 copies (%) p value ≥3 copies (%) p value ≥3 copies (%) p value
Total cases 115 13 (11.3) 7 (6.1) 22 (19.1)
Sex 0.446 0.838 0.395
Female 38 3 (23.1) 2 (28.6) 9 (40.9)
Male 77 10 (76.9) 5 (71.4) 13 (59.1)
Age 0.281 0.437 0.021
<60 33 2 (15.4) 1 (14.3) 2 (9.1)
≥60 82 11 (84.6) 6 (85.7) 20 (90.9)
Tumor size (cm) 0.717 0.985 0.032
<5 50 5 (38.5) 3 (42.8) 5 (22.7)
≥5 65 8 (61.5) 4 (57.2) 17 (77.3)
Depth of invasion 0.555 0.677 0.525
Tis–T1 16 1 (7.7) 1 (14.3) 4 (18.2)
T2–T4 99 12 (92.3) 6 (85.7) 18 (81.8)
Lymph node metastasis 0.581 0.629 0.506
Negative 44 4 (30.8) 2 (28.6) 7 (31.8)
Positive 71 9 (69.2) 5 (71.4) 15 (68.2)
TNM staging 0.918 0.531 0.729
I 9 1 (7.7) 0 (0) 1 (4.6)
II 33 3 (23.1) 1 (14.3) 5 (22.7)
III 66 9 (61.5) 5 (71.4) 14 (63.6)
IV 7 1 (7.7) 1 (14.3) 2 (9.1)
Tumor differentiation 0.083 0.594 0.107
High 39 2 (15.4) 2 (28.6) 4 (18.2)
Moderate 56 6 (46.1) 5 (71.4) 15 (68.2)
Low 20 5 (38.5) 0 (0) 3 (13.6)
Ki-67 MI (%) 0.022 0.255 0.015
<15 41 1 (7.7) 1 (14.3) 3 (13.6)
≥15 74 12 (92.3) 6 (85.7) 19 (86.4)
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Ki-67 MI were significant independent predictors (p < 0.05) 
in poor overall survival in GC patients (Table 4). The 
Kaplan–Meier curves for overall survival, according to the 
gene copy number, indicated that MET amplification, but 
not EGFR and ErbB2, was a significant prognostic factor 
for poor survival among GC patients (Fig. 2). Furthermore, 
comparison of overall survival among patients with EGFR, 
ErbB2 and MET high copy number indicated that MET 
amplification has significantly poorer outcome (Fig. 2d).
Discussion
In recent years, many studies performed to understand the 
association of the biological characteristics of GC with 
clinical outcomes of the patients. Current studies have 
focused more on understanding the molecular mechanisms 
of gastric carcinomas to help a more accurate diagnosis and 
selecting a more effective treatment. With regard to the dis-
covery of novel specific targeted therapeutics, these molec-
ular mechanisms may be helpful to achieve more efficient 
therapeutic outcomes (Yk et al. 2011). Recently, changes in 
the expression of growth factor receptors and their legends 
have been reported in various tumors that may be a bio-
logical marker in cancer malignancy. To date, many genetic 
changes have been reported in gastric carcinoma; among 
these, abnormalities of tyrosine kinas receptors are more 
noteworthy. Alterations in EGFR, ErbB2 and MET genes 
are considered to be the most frequent genetic alterations in 
various cancers (Tahara 1995; Nakajima et al. 1999). Pres-
ently, no available knowledge is about EGFR, ErbB2 and 
MET gene amplification or overexpression status in Iranian 
population. Hence, in the present study, we determined 
amplification and the overexpression status of these three 
genes in GC patients by Real-Time PCR-based assay. The 
method used in this study is according to YK et al.’s (2011) 
study method, but in contrast to some other studies such as 
Bang et al.’s (2010) study method, in which overexpression 
of HER2 protein determined by immunohistochemistry 
or HER2 gene amplification determined by fluorescence 
in situ hybridization represents the eligibility criteria for 
trastuzumab therapy of gastric cancer patients; Nakajima 
et al.’s (1999) study method in which amplification and 
overexpression of ErbB2 and MET were investigated by 
immunohistochemistry and Southern blot hybridization; 
and YK et al.’s (2011) study that used FISH method. EGF 
receptors mediate multiple signal transduction pathways in 
Fig. 1  QRT-PCR analysis of EGFR, ErbB2 and MET mRNA in 
patients with GC. The cDNA levels of genes were normalized to 
HPRT cDNA. The expression levels of EGFR, ErbB2 and MET in ≥3 
copies groups were significantly higher than <3 copies groups in 
patients with GC
Table 3  Correlation between 
mRNA expression and gene 
copy numbers in cancerous 
tissue samples
R correlation coefficient
Gene copy number
EGFR ErbB2 MET
R p value R p value R p value
mRNA level (2Ct) 0.631 0.009 0.652 0.023 0.715 <0.001
Table 4  Multivariate analysis of predictive prognostic factors
Significant p values are in bold
p value
EGFR ErbB2 MET
EGFR gene amplification 0.215 – –
ErbB2 gene amplification – 0.129 –
MET gene amplification – – 0.002
Sex 0.651 0.364 0.235
Age 0.164 0.712 0.631
Tumor size 0.007 0.009 0.013
Depth of invasion 0.211 0.294 0.622
Lymph node metastasis 0.365 0.327 0.347
TNM staging 0.468 0.631 0.164
Tumor differentiation 0.862 0.169 0.239
Ki-67 MI 0.003 0.006 0.002
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which extracellular signals are converted into intracellular 
changes in expression of the given genes where control cel-
lular growth and differentiation. Among the HER family 
receptors, EGFR and ErbB2 have been more considered in 
human cancers (Yk et al. 2011). Quantitative information 
about HER family expression levels in tumorous cells is 
necessary, not only for knowing the biological roles of EGF 
receptors, but also for clinical applications (Junttila et al. 
2003). The expression level of EGF receptors may correlate 
with prognosis, responses to chemotherapy and hormonal 
therapy (Arteaga 2002). In addition, treatment with EGFR 
inhibitors may provide a good results if applied in patients 
with overexpression of these receptors (Junttila et al. 2003). 
The best example for this is herceptin therapy that provides 
clinical benefit almost in patients with HER2 overexpres-
sion (Vogel et al. 2002). Gene amplification and expression 
status of EGFR and ErbB2 in GC have been analyzed in 
many previous studies (Sakai et al. 1986; Nakajima et al. 
1999; Yk et al. 2011; Atmaca et al. 2012; Kato et al. 2013). 
The reported frequencies of EGFR and ErbB2 gene expres-
sion in this cancer type were ranged from 5 to 30 %. The 
correlation between EGFR and ErbB2 gene amplification 
with prognosis in GC patients remains controversial. In this 
study, EGFR and ErbB2 gene amplification was, respec-
tively, present in 11.3 and 6.1 % of gastric tumor samples 
(Table 2). These frequencies are similar to the frequency of 
ErbB2 gene amplification in Nakajima et al.’s (1999) study 
on the Japanese population, significantly higher than Kato 
et al.’s (2013) study on the Japanese population, and signifi-
cantly lower than Yk et al.’s (2011) study on Chinese popu-
lation. Our results also demonstrated that EGFR and ErbB2 
gene amplification was positively correlated with EGFR 
and ErbB2 gene expression status (Table 3). Furthermore, 
EGFR gene amplification was significantly associated with 
Ki-67 MI in GC patients. In contrast to previous studies 
(Nakajima et al. 1999; Yk et al. 2011; Kato et al. 2013), 
Fig. 2  Kaplan–Meier curves for overall survival in patients with 
GC. a, b Cumulative survival shows no significant poor outcome in 
patients with EGFR and ErbB2 copy number ≥3 copies and <3 cop-
ies. c A significant poorer outcome is seen in patients with MET copy 
number ≥3 copies than those with <3 copies. d MET amplification 
has significantly poorer outcome among patients with EGFR, ErbB2 
and MET high copy number. p values were estimated using the log-
rank test. N.S: not significant
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no associations were found between ErbB2 gene amplifica-
tion and clinicopathological features in GC patients. EGFR 
and ErbB2 gene amplification, and overexpression status 
in gastric epithelial cells may be useful markers for malig-
nancy and poor prognosis in gastric cancer. Activation of 
MET signaling modulates tumor cell growth, invasion, sur-
vival and tumor angiogenesis (Liu et al. 2010). In gastric 
cancer, mutations of MET gene are extremely rare (Park 
et al. 2000; Lee et al. 2000; Chen et al. 2001) On the other 
hand, MET activation may have been mostly attributed to 
gene amplification and overexpression status. Previous 
studies have reported an increase in MET gene copy num-
ber 10–20 % in GC patients by a Real-Time PCR-based 
assay (Lee et al. 2011; Graziano et al. 2011) or by Southern 
blot analysis (Seruca et al. 1995; Tsujimoto et al. 1997). 
In the current study, MET gene amplification was detected 
in 19.1 % of gastric tumors (Table 2), which is close to 
Nakajima et al.’s (1999) study and significantly higher than 
Kato et al.’s (2013) study. Our results also shown that MET 
gene amplification was positively correlated with MET 
gene expression status (Table 3). Furthermore, EGFR gene 
amplification was significantly associated with age, tumor 
size and Ki-67 MI in GC patients, in contrast to Kuniyasu 
et al.’s (1993) and Nakajima et al.’s (1999) studies that 
gene amplification and overexpression of MET were sig-
nificantly associated with lymph node metastasis and depth 
of tumor invasion in gastric carcinoma. We found that 
MET gene amplification was correlated with poor prog-
nosis and poor survival in patients with gastric carcinoma 
(Fig. 2) (Table 4). These data suggest that the overexpres-
sion of these receptors may play an important role in the 
early stages of tumorigenesis. Comparing our results with 
other studies indicates the frequencies of EGFR, ErbB2 
and MET gene amplifications are various among the Asian 
populations.
EGFR, ErbB2 and MET genes are frequently amplified 
in gastric carcinoma. EGFR, ErbB2 and MET gene ampli-
fication is positively correlated with mRNA transcription. 
MET gene amplification correlates with a poor prognosis 
and poor survival in gastric carcinomas.
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